Equity · Currency in GBp · Last updated Jun 6, 2026
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological malignancies and tumours; and OXB-401 that is in pre-clinical stage for the treatment of liver indication; as well as OXB-40X, OXB-40Y, and OXB-40Z, which are in pre-clinical stage for liver indication. The company has collaborations with Boehringer Ingelheim, Immatics, Arcellx, Orchard, and Beam Therapeutics; an agreement with Homology Medicines; license and clinical supply agreement with Juno Therapeutics, Inc.; and master services and development agreement with AstraZeneca UK Ltd and Serum Life Sciences Ltd. The company also has a strategic collaboration with Kite Pharma to develop and commercialize CART-ddBCMA, a lead late-stage product candidate. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Looking to balance out your exposure to OXB.L? The ETFs below have the lowest correlation with OXB.L — they tend to move on their own, which can help reduce risk when OXB.L drops. The stock ideas table highlights individual companies that behave independently from OXB.L.
No Diversifiers Found for OXB.L
We do not have enough correlation history to rank diversifiers for this symbol yet.
Diversification Analysis
Build a portfolio that complements OXB.L
Add OXB.L to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.
